Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months

Launched by ALLIANCE FOR INTERNATIONAL MEDICAL ACTION · Apr 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether providing a special nutritional supplement called SQ-LNS (Small Quantity Lipid-based Nutrient Supplements) along with routine measles vaccinations can help increase the number of vaccinated children aged 6 to 23 months. The researchers want to see if this approach can improve vaccination rates in areas of Yobe State, Northeast Nigeria, compared to just giving vaccinations without the supplement. They will gather information through surveys from families, healthcare providers, and community health workers to understand their experiences, as well as the costs involved in the program.

To participate in the trial, children must be between 6 to 23 months old and live in specific areas of Yobe State. Parents or guardians need to give their consent for their child to join. Participants can expect to be part of surveys that track vaccination rates and gather feedback on the program’s effectiveness and acceptability. This trial aims to find out if combining nutrition with vaccinations can help protect more children from measles while also understanding what challenges families and health workers face in getting these services.

Gender

ALL

Eligibility criteria

• • Baseline and endline cross-sectional household surveys Inclusion criteria
• • Aged 12-23 months;
• • With oral informed consent of parent or legal guardian;
• • Residing in the catchment settlements of wards included in the study. Exclusion criteria
• • Included in the longitudinal follow-up.
• • Longitudinal follow-up survey Inclusion criteria
• • Aged 6-12 months;
• • With written informed consent of parent or legal guardian;
• • Residing in the catchment settlements of wards included in the study. Exclusion criteria
• • Acute malnutrition criteria as per the WHO definition (i.e. MUAC\< 125 or WHZ \< -2 or nutritional edema);
• • - Known medical complication that requires referral for hospitalization;
• • Known allergies to SQ-LNS or SQ-LNS contraindication;
• • Any other condition interfering with protocol adherence or the ability to give informed consent, in the judgment of the Field Investigator Sampling for HHS and LS will be carried out in three stages in each LGA using probability proportional to size (PPS).
• • Qualitative feasibility and acceptability survey Inclusion
• • Parent or legal guardian of a child aged 6-23 months and residing in the catchment settlements of wards included in the study, or Health worker of the ministry of health involved in the study,or Community representative or Community health workers;
• • With written informed consent.